|
|
Vaccine Detail
|
Autologous Cancer Testis Antigen Specific Dendritic Cell Vaccine |
| Vaccine Information |
- Vaccine Name: Autologous Cancer Testis Antigen Specific Dendritic Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: NY-ESO-1, MAGE-A1, and MAGE-A3 (NCT01241162)
- Immunization Route: Other
- Description: This vaccine uses autologous cancer testis (CT) antigen specific dendritic cell (DC) preceded by decitabine as a demethylating chemotherapy for patients with high-risk neuroblastoma, Ewings sarcoma, osteogenic sarcoma, rhabdomyosarcoma or synovial sarcoma. The mature DC is pulsed with overlapping peptides mixes derived from full-length NY-ESO-1, MAGE-A1, and MAGE-A3. (NCT01241162)
|
| Host Response |
|
|
| References |
NCT01241162: Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma [https://clinicaltrials.gov/study/NCT01241162]
|
|
